JSKN033 Injection

DRUG2 trials

Sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Conditions

Advanced Solid TumorNon Small Cell Lung Cancer (NSCLC)

Phase 1

JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

TerminatedNCT06226766

Jiangsu Alphamab Biopharmaceuticals Co., LtdAdvanced Solid Tumor

Start: 2024-01-18End: 2025-07-31Updated: 2025-09-10

Phase 2

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruitingNCT07283198

Jiangsu Alphamab Biopharmaceuticals Co., LtdNon Small Cell Lung Cancer (NSCLC)

Start: 2025-12-10End: 2027-08-30Target: 160Updated: 2025-12-15